Is there an official GHK-Cu injection frequency?

No. Unlike an FDA-approved drug with a labeled dosing schedule, GHK-Cu has no approved injectable label, so no regulatory body has set a required frequency. Frequency in research write-ups varies by protocol.

Does GHK-Cu injection frequency change the reconstitution math?

No. Frequency determines how many times you draw from a vial. Concentration is set once, at reconstitution, by vial mass divided by water volume, and stays the same no matter how often you draw.

How do I work out how long a GHK-Cu vial will last at a given frequency?

Divide the vial's total mg by the target dose to get doses per vial, then divide that by how often you draw. A 100 mg vial dosed at 2 mg holds 50 doses — 50 days at once daily, or 100 days at every other day.

Does a higher GHK-Cu injection frequency mean a smaller dose?

Not necessarily. Frequency and dose size are separate choices in a research protocol. A protocol can pair a higher frequency with a smaller per-draw dose or keep the dose the same and simply draw down the vial faster — the arithmetic doesn't force one over the other.

GHK-Cu Injection Frequency Explained

By PeptCalc Research — Medically reviewed by David Mansour, MD — Last reviewed July 24, 2026

GHK-Cu injection frequency is not something a drug label specifies, because GHK-Cu has no approved injectable label to specify it. That puts it in a different position from an FDA-approved peptide, where frequency is fixed by regulatory review. This reference explains what determines frequency in GHK-Cu research protocols instead, and — more usefully — how frequency interacts with the reconstitution math that decides how long a vial actually lasts. It is written for research and educational purposes only and is not medical advice.

No approved label sets a fixed frequency

Some research peptides have an FDA-approved formulation with a specific labeled schedule; tesamorelin, for example, carries an approved once-daily label for its narrow indication, indexed on DailyMed (NIH/NLM). GHK-Cu does not have an equivalent approved injectable drug label. Without that regulatory anchor, there is no single "correct" GHK-Cu injection frequency the way there is for a handful of approved peptides — only frequencies that show up across different research write-ups and protocols, which vary from source to source.

That absence of a fixed standard is consistent with how GHK-Cu is treated elsewhere on this site: there's no official standard water volume for reconstitution either, only reference concentrations chosen because they read cleanly on a syringe. Frequency works the same way — a protocol detail set by whoever designed the specific research use, not a number handed down from an approved label.

What frequency actually controls

Frequency answers one question: how many times per period does a draw come out of the vial. It does not answer a separate question: what is the concentration of what's in the vial. That second question is fixed the moment bacteriostatic water is added:

Concentration = vial mass (mg) ÷ water added (mL)

A vial reconstituted to a given concentration stays at that concentration through every draw, whether the schedule calls for one draw a day or one draw a week. Frequency and concentration are independent variables that happen to combine into a third, more practical number: how many days a single vial will actually cover.

Worked example: vial life at two frequencies

Take a 100 mg GHK-Cu vial reconstituted with 5 mL of bacteriostatic water, at a 2 mg target dose per draw — the same reference setup used in the GHK-Cu dosage chart.

Step 1 — concentration. 100 mg ÷ 5 mL = 20 mg/mL.

Step 2 — volume per dose. 2 mg ÷ 20 mg/mL = 0.1 mL.

Step 3 — syringe units. On a U-100 insulin syringe, 1 mL = 100 units, so 0.1 mL × 100 = 10 units per draw.

Step 4 — doses per vial. 100 mg ÷ 2 mg = 50 doses. This number depends only on vial mass and dose size — the water volume chosen in Step 1 doesn't change it.

Step 5 — vial life by frequency. At once daily, 50 doses run 50 days, or about 7.1 weeks. At every other day, the same 50 doses stretch to 50 × 2 = 100 days, or about 14.3 weeks. Neither frequency is presented here as a recommendation — they're two illustrative points to show how the same vial and dose produce very different vial-life numbers depending on how often it's drawn.

The 50 mg vial follows the identical formula at a lower total. Reconstituted with 2 mL of water (25 mg/mL, giving 8 units for a 2 mg dose, matching the dosage chart), it holds 50 mg ÷ 2 mg = 25 doses. At once daily that's 25 days (about 3.6 weeks); at every other day, 50 days (about 7.1 weeks).

Vial size	Water added	Concentration	2 mg dose (units)	Doses per vial	Vial life — once daily	Vial life — every other day
50 mg	2 mL	25 mg/mL	8 units	25	25 days (~3.6 weeks)	50 days (~7.1 weeks)
100 mg	5 mL	20 mg/mL	10 units	50	50 days (~7.1 weeks)	100 days (~14.3 weeks)

Frequency and dose size are separate decisions

It's easy to assume a higher GHK-Cu injection frequency automatically means a smaller per-draw dose, since that pattern shows up in some protocols. The arithmetic doesn't require it. A protocol can hold the dose steady and simply draw from the vial more often — which draws the vial down faster and shortens vial life — or it can lower the dose to stretch the same vial across more frequent draws. Frequency, dose size, and vial life are three separate numbers connected by the doses-per-vial formula above; changing one doesn't automatically change another unless the protocol is designed that way.

Why research protocols on frequency disagree

Because there's no approved label to converge around, published and self-reported GHK-Cu protocols describe a range of schedules rather than one standard. Some describe daily draws; others space them out. This guide does not recommend a frequency or take a position on which protocol is better — that's a research design question outside the scope of a reconstitution reference, and outside what a peptide calculator can tell you. What the math above can tell you is how any given frequency plays out against a specific vial size, water volume, and dose once you've settled on one.

Keeping frequency and concentration from drifting apart

A frequency-based vial-life estimate is only accurate if the concentration behind it hasn't changed. Track the date a vial was reconstituted, not just when it was opened — see how to store reconstituted peptides for the general reasoning. If a vial that should supply 50 doses at 20 mg/mL runs out sooner than the frequency and dose size predict, the concentration used in the original calculation is the more likely source of the mismatch, not the compound itself.

Common mistakes

Looking for an official GHK-Cu injection frequency. No approved label sets one — treat any specific number as a protocol detail, not a standard.
Assuming frequency changes concentration. It doesn't. Concentration is fixed at reconstitution; frequency only affects how fast the vial's total mg gets drawn down.
Reusing a vial-life estimate after changing the water volume or dose. The 50-day and 100-day figures above only hold at 20 mg/mL and a 2 mg dose. Change either input and the vial-life number changes with it.
Confusing dose size with frequency. They're independent choices, not two names for the same variable.

Use the calculator

Enter your GHK-Cu vial size, bacteriostatic water volume, and target dose into the peptide calculator to get the exact concentration, draw volume, and syringe units, then apply your intended frequency to the doses-per-vial figure to estimate vial life. For the full mixing steps, see the GHK-Cu reconstitution calculator guide; for how vial size alone affects total supply, see the GHK-Cu vial size guide.